With April 1 as the starting point, Horizon Therapeutics expects to put a stop to the supply issues which have affected the company's new and highly popular launch Tepezza since December last year, which the firm states in a press release.
The firm's solution, as it turns out, is that it has received approval from the US Food and Drug Administration (FDA) to introduce a new production setup, which allows Horizon Therapeutics to produce more of the drug itself, rather than outsourcing this task to contractors.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
New CCO at crisis-hit Lundbeck: "2022 will be a growth year for Lundbeck in all regions"
Jacob Tolstrup will be responsible for renewing sales growth at Lundbeck, having made his way through the ranks.
Coloplast upgrades growth expectations following acquisition
Medtech firm Coloplast’s Q1 report for 2021/2022 brings a slight upward adjustment of the reported revenue growth outlook due to foreign exchange developments. Coloplast’s acquisition of Atos Medical is expected to contribute around 6 percent to organic growth.
Demant's surgical division loses president of 13 years
Oticon Medical, the implants division at hearing group Demant, is saying goodbye to President Jes Olsen, who is exiting his role in March after having spearheaded the business leg since 2008. Demant CEO Søren Nielsen is stepping in temporarily until a replacement is found.
Hearing aid market in US grew by 37 percent in 2021
Hearing aid manufacturers have had a good year following one of the worst in their recorded history, as sales in the US have gone up by 37 percent. The progress is mainly driven by the recovery of independent retailers, whereas public sales channel Veterans Affairs still lags behind.
Lundbeck's migraine drug approved in EU
Vyepti has become the first approved intravenous preventative migraine treatment in the region.
Clinical Research Associate 
Senior Director, Global Regulatory Lead 
Compound Development Team Lead 
Associate Director, GMP QA, Biologics/Radiopharmaceuticals 
NORDIC Medical Sales Director 
QA Specialist 
Chemists are wanted for ALK's internal Aircraft Corps 
GxP QA Compliance Manager for Quality Assurance 
Director Regulatory Affairs 
Senior Design Control Engineer, Design Control and Risk Management, ALK 
Head of Bioinformatics, Muna Therapeutics 
Health Economist